Treatment-related osteoporosis in men with prostate cancer

Area of Science:

• Endocrinology
• Bone Metabolism
• Men's Health

Background:

• Gonadotropin-releasing hormone (GnRH) agonists are used therapeutically but induce hypogonadism, a key factor in acquired male osteoporosis.
• GnRH agonists accelerate bone turnover and reduce bone mineral density, increasing fracture risk.
• Estrogen deficiency, not testosterone deficiency, is implicated as the primary driver of adverse skeletal effects from GnRH agonists.

Purpose of the Study:

• To review the skeletal effects of GnRH agonists in men.
• To summarize evidence on fracture risk associated with GnRH agonist therapy.
• To discuss interventions for managing bone loss during GnRH agonist treatment.

Main Methods:

• Review of claims-based analyses and retrospective studies on GnRH agonists and fracture risk.
• Analysis of randomized controlled trials evaluating bone mineral density changes.
• Consideration of ongoing prospective studies on fracture outcomes and novel interventions.

Main Results:

• Retrospective studies indicate GnRH agonists elevate clinical fracture risk.
• Bisphosphonates (pamidronate, zoledronic acid) and SERMs (raloxifene, toremifene) improved bone mineral density in men receiving GnRH agonists.
• Estrogen deficiency is identified as the main cause of bone density loss.

Conclusions:

• GnRH agonists negatively impact male skeletal health, increasing fracture risk.
• Pharmacologic interventions like bisphosphonates and SERMs can improve bone mineral density in men treated with GnRH agonists.
• Further prospective studies are evaluating fracture outcomes and novel treatments for men on GnRH agonists.